comparemela.com

Latest Breaking News On - Therapeutics first quarter - Page 1 : comparemela.com

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

Arcturus Therapeutics Holdings Inc. , a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases,.

ARCTURUS THERAPEUTICS HOLDINGS INC : Stock Market News and Information | ARCT| US03969T1097

ARCTURUS THERAPEUTICS HOLDINGS INC. : News, information and stories for ARCTURUS THERAPEUTICS HOLDINGS INC. | Nasdaq: ARCT | Nasdaq

Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results

Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results Marker continues to advance Phase 2 AML trial, recently dosing first patient Company closed financing extending cash runway into Q1 2023 Company to host conference call and webcast today at 5:00 p.m. ET News provided by Share this article Share this article HOUSTON, May 12, 2021 /PRNewswire/ Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.   We had a productive first quarter supported by our recently completed financing, strengthening our overall cash position and enabling continued growth and expansion of our Multi-TAA pipeline, said Peter L. Hoang, President & CEO of Marker Therapeutics. In add

Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021

Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021 News provided by Share this article Share this article HOUSTON, April 29, 2021 /PRNewswire/  Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, May 12, 2021 at 5:00 p.m. Eastern Time to review its first quarter 2021 financial and operating results and provide a corporate update. The webcast will be accessible in the Investors section of the Company s website at markertherapeutics.com. Individuals can participate in the conference call by dialing 877-407-8913 (domestic) or 201-689-8201 (international) and referring to the Marker Therapeutics First Quarter 2021 Earnings Call.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.